Work

Population-adjusted indirect comparison (PAIC) of avelumab (AVE) and retifanlimab (RETI) in the first-line (1L) treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC).

Year: 2025

Type: article

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e21513

Authors: Mairead Kearney, Karin Tyroller, Loraine Monfort, Vikas Jangra, Hoora Moradian

Institutions: Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), EMD Serono, Inc. (United States)

Language: English

Topic: Polyomavirus and related diseases

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410805499

FWCI:

Cites:

Cited by:

Related to: 10